Experienced in Venous Thromboembolism (VTE)

Dr. John M. Hoffman

Nuclear Medicine | Radiology
50 N Medical Dr, 1a71, 
Salt Lake City, UT 
Experienced in Venous Thromboembolism (VTE)
50 N Medical Dr, 1a71, 
Salt Lake City, UT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Hoffman is a Nuclear Medicine specialist and a Radiologist in Salt Lake City, Utah. Dr. Hoffman is rated as an Experienced provider by MediFind in the treatment of Venous Thromboembolism (VTE). His top areas of expertise are Lung Nodules, Venous Thromboembolism (VTE), and Renal Cell Carcinoma (RCC).

His clinical research consists of co-authoring 64 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Venous Thromboembolism (VTE).

Specialties
Nuclear Medicine
Radiology
Licenses
Nuclear Medicine in UT
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

50 N Medical Dr, 1a71, Salt Lake City, UT 84132

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Development of an Integrated Molecular Biomarker ofEarly Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients Using Imaging Assessments and Genomic Modeling
Development of an Integrated Molecular Biomarker ofEarly Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients Using Imaging Assessments and Genomic Modeling
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Radiation, Drug
Study Drugs: Erlotinib, Bevacizumab
Study Phase: Phase 1
[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors
[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors
Enrollment Status: Terminated
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: 18F-Fluciclovine, 18F-FLT
Study Phase: Phase 1/Phase 2
Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial
Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial
Enrollment Status: Terminated
Publish Date: December 09, 2024
[18F]Fluciclovine Companion Imaging Study to Radium-223 and Radiotherapy in Hormone-Naive Men With Oligometastatic Prostate Cancer to Bone (RROPE) Study
[18F]Fluciclovine Companion Imaging Study to Radium-223 and Radiotherapy in Hormone-Naive Men With Oligometastatic Prostate Cancer to Bone (RROPE) Study
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug, Procedure
Study Drug: Fluciclovine
Study Phase: Phase 2
Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment
Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment
Enrollment Status: Terminated
Publish Date: November 20, 2024
Intervention Type: Drug, Diagnostic test
Study Drugs: [18F]Flutemetamol, [18F]fluoro-2-deoxy-D-glucose
Study Phase: Phase 2
Assessment of Primary and Metastatic Brain Tumor Hypoxia With 18F-Fluoromisonidazole, [18F]Fluoro-2-deoxy-D-glucose (FDG) and [15O]Water (H215O)
Assessment of Primary and Metastatic Brain Tumor Hypoxia With 18F-Fluoromisonidazole, [18F]Fluoro-2-deoxy-D-glucose (FDG) and [15O]Water (H215O)
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Diagnostic test, Drug
Study Phase: Phase 1
Multi-tracer PET Assessment of Response in Various Malignancies in Investigational and Recently Approved Therapeutic Agents
Multi-tracer PET Assessment of Response in Various Malignancies in Investigational and Recently Approved Therapeutic Agents
Enrollment Status: Terminated
Publish Date: April 17, 2024
Intervention Type: Radiation, Procedure
Study Phase: Not Applicable
A Multi-modality Imaging Assessment of Chemobrain
A Multi-modality Imaging Assessment of Chemobrain
Enrollment Status: Completed
Publish Date: March 15, 2024
Intervention Type: Drug
Study Phase: Phase 1
Implications for Management of PET Amyloid Classification Technology
Implications for Management of PET Amyloid Classification Technology
Enrollment Status: Completed
Publish Date: April 24, 2023
Intervention Type: Drug
Multi-Tracer Positron Emission Tomography (PET) Prediction and Assessment of Response to Gemcitabine in Pancreatic Cancer Patients
Multi-Tracer Positron Emission Tomography (PET) Prediction and Assessment of Response to Gemcitabine in Pancreatic Cancer Patients
Enrollment Status: Completed
Publish Date: October 15, 2021
Intervention Type: Device
Study Phase: Not Applicable
Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab
Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab
Enrollment Status: Withdrawn
Publish Date: February 07, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

64 Total Publications

Using neuropsychological test scores to predict beta-amyloid deposition in older adults across the late-life cognitive continuum.
Using neuropsychological test scores to predict beta-amyloid deposition in older adults across the late-life cognitive continuum.
Journal: Journal of clinical and experimental neuropsychology
Published: October 25, 2025
Similar Doctors
Experienced in Venous Thromboembolism (VTE)
Dr. Kathryn A. Morton
Radiology
Experienced in Venous Thromboembolism (VTE)
Dr. Kathryn A. Morton
Radiology

University Hospital Adult Services

50 North Medical Drive, 
Salt Lake City, UT 
 (0.1 miles away)
801-585-0067
Experience:
44+ years
Languages Spoken:
English
See accepted insurances

Kathryn Morton is a Radiologist in Salt Lake City, Utah. Dr. Morton has been practicing medicine for over 44 years and is rated as an Experienced provider by MediFind in the treatment of Venous Thromboembolism (VTE). Her top areas of expertise are Neuroendocrine Tumor, Lymphofollicular Hyperplasia, Smoldering Multiple Myeloma, and Fibrolamellar Carcinoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hoffman's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile